FDA Advisory Committee To Discuss ANORO ELLIPTA; Theravance Stock Halted

(RTTNews) - Theravance Inc. (THRX) announced that its common stock has been halted from trading on the morning, September 10, 2013 by NASDAQ. The Pulmonary-Allergy Drugs Advisory Committee to the U.S. FDA will meet on Sept. 10 to discuss the new molecular entity New Drug Application for umeclidinium bromide and vilanterol dry powder for inhalation (proposed trade name ANORO ELLIPTA), for the long-term, once-daily, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

UMEC/VI is in development under the LABA collaboration agreement between Glaxo Group Limited (GSK.L, GSK) and Theravance Inc.